Eupraxia Pharmaceuticals Inc. EPRX
8.06 USD +0.43 (+5.64%)
At closeNov 11, 2026, 4:00 PM EST
8.06 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
7.96 Day range 8.49
5.63 52-week range 9.32
- YTD
- +6.75%
- 1 year
- +23.43%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Raises Price Target to $16 HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and raises the price target from $11 to $16.
benzinga.com Eupraxia Announces $125M At-The-Market Equity Program; Says No Current Plan To Use ATM Program In Near Term Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…
globenewswire.com Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…
benzinga.com Eupraxia Pharmaceuticals Q3 EPS $(0.23) Beats $(0.28) Estimate Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 17.86 percent. This is a 21.05 percent decrease over…
globenewswire.com Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…- benzinga.com RBC Capital Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $14 RBC Capital analyst Douglas Miehm initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $14.
globenewswire.com Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…
benzinga.com Eupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial The Company has a statistical team who are doing periodic reviews of the…
globenewswire.com Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…
globenewswire.com Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…
benzinga.com HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
globenewswire.com Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…
benzinga.com Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17 Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
globenewswire.com Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-market session. The company's market cap stands at $5.6 million. Nyxoah (NASDAQ:NYXH) shares increased by…
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
globenewswire.com Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post…
benzinga.com Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from…
globenewswire.com Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
zacks.com Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward…
defenseworld.net Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of “Moderate Buy” by Brokerages Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm,…
globenewswire.com Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company…
globenewswire.com Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…
benzinga.com Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17 Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
globenewswire.com Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company…
globenewswire.com Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…
benzinga.com VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.
benzinga.com Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS…
benzinga.com This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-ratings. Considering SAIL stock? Here's what analysts say.- benzinga.com Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25 Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.
- benzinga.com Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 9.52 percent decrease over…
globenewswire.com Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional…
globenewswire.com Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue…
benzinga.com Eupraxia Reports Early Trial Results For EoE Drug, Doses Show Response In Mid-Stage Study Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…
globenewswire.com Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data…- benzinga.com HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
globenewswire.com Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…- benzinga.com HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
globenewswire.com Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…- benzinga.com Eupraxia Pharma Announces 36-Week Tissue Health And Symptom Data From Patients In Highest Dose Cohort From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of EoE This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia's RESOLVE trial. At 36 weeks, patients in…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
benzinga.com Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased…- benzinga.com Eupraxia Reports Up To 76% Remission In Study, Advances Next Phase Of Treatment Development Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…
- benzinga.com HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Lowers Price Target to $11 HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and lowers the price target from $12 to $11.
benzinga.com Eupraxia Pharmaceuticals Q4 EPS $(0.37) Misses $(0.16) Estimate Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.16) by 131.25 percent. This is a 68.18 percent decrease over…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Eupraxia Pharmaceuticals Commences Common Stock Offering; Terms Not Disclosed Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Cantor Fitzgerald Maintains Overweight on Eupraxia Pharmaceuticals, Raises Price Target to $19 Cantor Fitzgerald analyst Kristen Kluska maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight and raises the price target from $11 to $19.